Findings

What do systematic reviews say?

16 questions · 16 findings · 2 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 12.5%GRADE not reported 0 · 0%Very low 2 · 12.5%Low 6 · 37.5%Moderate 6 · 37.5%High 0 · 0%

SGLT2 inhibitors vs placebo

Transplant or graft survival · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Moderate

SGLT2 inhibitors vs placebo

Delayed graft function · pre‐existing and new‐onset diabetes in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

SGLT2 inhibitors vs placebo

HbA1c (%) · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Low

SGLT2 inhibitors vs placebo

FBG (mmol/L) · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Low

SGLT2 inhibitors vs placebo

Kidney function markers · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Low

SGLT2 inhibitors vs placebo

Death (any cause) · pre‐existing and new‐onset diabetes in kidney transplant recipients

The review found no eligible studies for this question.

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

SGLT2 inhibitors vs placebo

Hypoglycaemia · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 44 participants
Moderate

SGLT2 inhibitors vs placebo

Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients

1 finding from 1 review

Glucose‐lowering agents for treating pre‐existing and new‐onset diabetes in kidney transplant recipients 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Moderate

SGLT2 inhibitors vs placebo

HbA1c (%) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1092 participants
Moderate

SGLT2 inhibitors vs placebo

FBG (mmol/L) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 855 participants
Moderate

SGLT2 inhibitors vs placebo

Death (all causes) · people with diabetes and CKD

1 finding from 1 review · compare the 2 reviews

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 2933 participants
Very low

SGLT2 inhibitors vs placebo

All cardiovascular death · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2788 participants
Low

SGLT2 inhibitors vs placebo

Weight (kg) · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1029 participants
Low

SGLT2 inhibitors vs placebo

eGFR · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 848 participants
Moderate

SGLT2 inhibitors vs placebo

Hypoglycaemia · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 3086 participants
Low

SGLT2 inhibitors vs placebo

Discontinuation of medication due to adverse events · people with diabetes and CKD

1 finding from 1 review

Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 917 participants
Very low